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Background
Ipilimumab is a fully human antibody that blocks CTLA-4
and has proven to extend overall survival in patients with
unresectable stage III or stage IV melanoma. There is a
need for well-documented pharmacodynamic markers
together with potential predictive biomarkers that may
allow for pretreatment selection of patients and screening
for IRAE. Most of the recently published immune monitor-
ing studies focus mainly on the effect that ipilimumab has
on T cell populations. An in-depth immune monitoring
study was conducted in advanced melanoma patients
undergoing treatment with ipilimumab. The main focus of
this work was to analyze the effect of ipilimumab treatment
on peripheral blood MDSC populations as well as T cells.
Materials and methods
Six patients with advanced stage melanoma received ipili-
mumab treatment at 3 or 10 mg/kg doses as part of dou-
ble blind randomized trial CA184-169. Twenty-four
additional patients received 3 mg/kg doses. Blood samples
were collected before treatment (baseline) and at the time
of the second and fourth ipilimumab doses. Peripheral
blood mononuclear cells were isolated by density gradient
centrifugation and stained for flow cytometric analysis
within two hours of sample collection.
Results
In the thirty patients included, median OS was 38 weeks
from the start of treatment. Adverse events were observed
in 12 patients (40%), including seven grade III-IV (23%).
Patients were classified according to their response as PD
(progressive disease, 57%), SD (stable disease, 23%) and PR
(partial response, 20%).
ICOS+CD4+ T cell frequency was significantly increased
after Ipilimumab treatment, suggesting an increase in the
activation of this cellular population. The endpoint mean
frequency of Tregs was significantly lower than the base-
line. In addition to this, changes in the suppressive mye-
loid compartment were also observed, with significant
reductions in the frequency of granulocytic MDSCs. The
suppressive potential of both granulocytic and monocytic
MDSCs was also diminished, as the frequencies of Arg1+
and iNOS+ cells were reduced after treatment. Further
analysis showed that the populations of granulocytic
MDSCs and CD4+ICOS+ T cell populations presented a
statistically significant correlation.
Conclusions
Ipilimumab treatment can be acting in two very distinct
ways: on one hand it is increasing the activation status of
T cells and on the other hand, it is decreasing the frequen-
cies of suppressive cells such as Tregs and granulocytic
MDSCs. These effects, and their possible correlations to
clinical benefit, should be further explored.
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